^
Association details:
Biomarker:No biomarker
Cancer:Nasopharyngeal Carcinoma
Drug:doxorubicin hydrochloride (Topoisomerase II inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published date:
12/21/2020
Excerpt:
Nasopharyngeal carcinoma: Recommendations...management of advanced/metastatic disease...active agents include paclitaxel, docetaxel, 5-FU, capecitabine, irinotecan, vinorelbine, ifosfamide, doxorubicin, oxaliplatin and cetuximab, which can be used as single agents or in selected combinations.
DOI:
10.1016/j.annonc.2020.12.007